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Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although
there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have
limited eﬃcacy and pose signiﬁcant risks of toxicity. Moreover, prognosis of patients with SLE has remained diﬃcult to assess.
TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sj¨ ogren’s
syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for
decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles
in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses
and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF)
family and regulates type I interferon and proinﬂammatory cytokines. In this paper, we summarize molecular features of TRIM21
revealed so far and discuss its potential as an attractive therapeutic target for SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic, systemic,
andautoimmune disease ofunknown etiology. The disease is
characterized by the presence of a variety of autoantibodies
in patients’ sera, including those speciﬁc for nuclear antigens
called antinuclear antibodies (ANA). Although current ther-
apies of SLE largely rely on glucocorticoids and immunosup-
pressant drugs, the eﬃcacy is limited so far and there hold
signiﬁcant risks of toxicity. In order to better understand the
pathogenesis and ﬁnd new therapeutic designs, a systemic
characterization of the molecular and cellular basis of signal-
ing abnormalities in the immune system that lead to autoim-
mune response and inﬂammation is urgently required.
In sera of patients with SLE and Sj¨ ogren’s syndrome
(SS), another systemic autoimmune disease, an ANA speciﬁc
for an autoantigen called Ro (also called SS-A) has been
known since the 1960s [1–3]. While anti-Ro antibodies are
found primarily in patients with SLE and SS, they are also
sometimesseeninothersystemicautoimmunediseases,such
as systemic sclerosis, polymyositis/dermatomyositis, mixed
connective tissue disease, and rheumatoid arthritis [4, 5].
Although these anti-Ro antibodies have been used as a useful
diagnostic marker for SLE and SS for decades, the molecular
identity of Ro autoantigen had not been clariﬁed for a long
time. Later, Ro antigen was found to consist of two proteins,
Ro52 (also called TRIM21, SSA1, or RNF81) and Ro60 (also
called SSA2 or TROVE2), which seem to have functions not
directly related to each other [6–8].
Anti-Ro antibodies have been reported to be associated
with photosensitivity, subacute cutaneous lupus, cutaneous
vasculitis, hematological disorder, interstitial lung disease,
and neonatal lupus including congenital heart block [5, 9–
15]. The anti-Ro antibodies are associated with the HLA-
DR3 and/or DR2 haplotype and C4 complement component2 International Journal of Rheumatology
Table 1: SLE/SS-related SNP in TRIM21 gene.
Location (position)∗ Reference SNP ID Nucleotide change Genotype frequency (%) P Value Reference
5 -UTR rs5030767 Ab(+) pSS HC
(4595) (n = 38) (n = 72)
C/C 60.5 83.3 0.029 [22]
C/T 34.2 13.9
T/T 5.3 2.8
Intron 1 rs7947461 Ab(+) pSS Ab(−)p S S
(7216) (n = 39) (n = 23)
A/A 25.6 4.3 0.028 [23]
A/G 56.4 52.2
G/G 17.9 43.5
Intron 1 rs660 SLE HC
(7219) (n = 26) (n = 29)
C/C 3.8 34.5 <0.0005 [20, 21]
C/T 26.9 44.8
T/T 69.2 20.7
Intron 1 rs5030768 Ab(+) pSS HC
(7649) (n = 38) (n = 72)
A/A 57.9 80.5 0.038 [22]
A/G 34.2 16.7
G/G 7.9 2.8
Intron 3 rs915956 Ab(+) pSS HC
(9571) (n = 38) (n = 72)
C/C 44.7 84.7 0.00003 [22]
C/T 52.6 12.5
T/T 2.6 2.8
3 -UTR rs4144331 Ab(+) pSS HC
(12986) (n = 38) (n = 72)
C/C 71.1 87.5 0.033 [22]
C/A 28.9 12.5
∗Position in the gene according to GenBank accession no. UO1882. UTR, untranslated region; Ab(+), anti-TRIM21 antibody-positive; pSS, primary SS, HC,
healthy control; Ab(−), anti-TRIM21 antibody-negative.
deﬁciency [16, 17]. Among the anti-Ro antibodies, anti-
TRIM21/Ro52 antibodies have been used for diagnosis and
monitoring and have been shown to act as a pathological
factor [18, 19].
The TRIM21 gene has also been linked to the diseases,
although the sample numbers were small in the reported
studies. These studies suggest possible associations between
allelic polymorphisms of TRIM21 and the disease suscep-
tibility and increased anti-TRIM21 antibodies in SLE and
SS(Table 1).Thers660C/Tsingle-nucleotide polymorphism
(SNP) has been shown to be associated with SLE in African
Americans [20, 21]. In this SNP, population size of rs660C/C
in patients with SLE was around one ninth of that in healthy
controls. The rs5030767 C/T, rs5030768 A/G, rs915956 C/T,
and rs4144331 C/A SNPs were shown to be associated with
anti-TRIM21 antibody-positive primary SS in a Norwegian
population, among which rs915956 shows the strongest
association [22]. Population size of rs915956C/C in anti-
TRIM21 antibody-positive patients with SS was about one
half of that in healthy controls. The rs7947461 A/G SNP
is one of genetic factors involved in Japanese SS [23].
rs7947461A/A population inanti-TRIM21antibody-positive
patients withSSwassix times aslargeasthatin anti-TRIM21
antibody-negative patients.
Furthermore, about a twofold increase in the expression
ofTRIM21transcriptsinperipheralbloodmononuclearcells
(PBMC) of patients with SLE and SS as compared with
healthy controls has been reported, although data on protein
levels was not shown [24]. Thus, not only the antibodies
to TRIM21 but also the TRIM21 antigen itself has been
suggested to have a role, in some way, in the pathogenesis
of SLE and SS [25]. In this paper, we focus on the nature and
function of the TRIM21 molecule and discuss its potential as
a therapeutic target of systemic autoimmune diseases.International Journal of Rheumatology 3
2. The TRIM21 GeneLocus,Molecular
Structure,and ExpressionPattern
In 1991, two independent groups cloned the cDNA of
human TRIM21, a 475-aa and 52-kDa protein [26, 27].
Subsequently, the human TRIM21 gene was mapped to the
region 11p15.5 on chromosome 11 and the exon-intron
structure was clariﬁed [20, 28, 29]. The murine homologue,
Trim21, has also been cloned [30]. The amino acid sequence
identity between the murine and the human TRIM21
proteins is 69.9%, and when conservative substitutions were
taken into account, the similarly increases to 81.5%. The
identity is much higher in regions containing predicted
functional domains [30]. The TRIM21 gene is 8.8kb (in
human) or 7.5kb (in mouse) in size, consisting of 7 (in
human) or 8 (in mouse) exons with conserved exon-intron
structure. There are two large regions of closely related
TRIM gene clusters in the human and murine genomes
[31]. First, TRIM10, TRIM15, TRIM26, TRIM31, TRIM39,
and TRIM40 are located in the major histocompatibility
complex region on chromosome 6 in human and 17 in
mouse. Second, TRIM3, TRIM5, TRIM6, TRIM21, TRIM22,
TRIM34, TRIM66,a n dTRIM68 are located on chromosome
11 in human and 7 in mouse.
The TRIM21 protein belongs to the tripartite motif-
containing (TRIM) superfamily by its molecular structure
[32, 33]. A common structural feature of the TRIM super-
family is the highly conserved RBCC motif, containing
the RING, B-box, and coiled-coil domains in this order
[31, 34]. TRIM proteins exhibit a wide range of activities,
including the regulation of innate and adaptive immunity
[33]. Interestingly, TRIM68, encoded by a gene that is
adjacent to TRIM21, has a structure that is similar to
TRIM21. TRIM68 is another autoantigen, SS-56, found in
patients with SLE and SS [35]. The N terminus of TRIM21
has the RING domain (aa 15–58 in human) with two Zn2+-
binding sites and the B-box domain (aa 91–128) with one
Zn2+-bindingsite[26].Themiddlepartoftheprotein,which
includes the leucine zipper, has a coiled-coil structure (aa
125–235). The C terminus of TRIM21 contains a PRYSPRY
domain (aa 286–465; also referred to as B30.2) also found in
many other TRIM proteins [36, 37].
TRIM21 is expressed ubiquitously as determined by in
situ hybridization [32, 38–41]. Recently, more precise distri-
butionpatternswereanalyzedforTRIM21usingTrim21-null
mice with an enhanced green ﬂuorescent protein (EGFP)
reporter gene by two independent groups [42, 43]. TRIM21
is expressed at the highest levels in immune organs, such
as lymph nodes, spleen and thymus in the mice. Among
leukocyte subsets, TRIM21 expression is generally high in T
cells, natural killer T cells, and macrophages and dendritic
cells, but lower in B cells and granulocytes, although the
levels varied for cells in each type [42]. For example, among
B cell subsets, B-1a cells expressed TRIM21 levels twice that
of plasma cells. Within dendritic cell (DC) subsets, TRIM21
levels were higher in the conventional DCs (cDCs) than
plasmacytoid DCs (pDCs).
TRIM21 expression levels vary substantially during the
early development of both the B and T cell lineages [42]. As
for intracellular localization, TRIM21 mostly resides in the
cytoplasm, although low levels are also found in the nucleus
[44, 45]. A study with overexpressed recombinant GFP-
TRIM21 fusion protein showed that full-length TRIM21 is
almost exclusively localized in the cytoplasm while dele-
tion mutants lacking the coiled-coil domain spread evenly
throughout the cell, suggesting that the cytoplasmic localiza-
tion of TRIM21 is mediated by the coiled-coil region [46].
In the cytoplasm, TRIM21 has been shown to localize in
unidentiﬁed distinct structures called “cytoplasmic body,”
which is located along the microtubule network [32, 47, 48].
TRIM21 has been extensively documented as an
interferon- (IFN-) inducible protein in various cell types
[41–43,47,49–52].TRIM21isalsoinducedbyviralinfection
or Toll-like receptor (TLR) engagement via type I IFN
induction [42, 50, 53]. TRIM21 is translocated from the
cytoplasm into the nucleus upon IFN-α stimulation [47, 50].
On the other hand, TRIM21 translocation in the cell is
also mediated by other stimulations. It has been reported
that TRIM21 translocates from the cytoplasm to cell surface
in apoptotic or stressed cells. TRIM21 is translocated to
apoptotic blebs and associated with the plasma membrane in
apoptotic endothelial cells [54]. A similar translocation has
also been demonstrated in apoptotic fetal cardiomyocytes
[55, 56]. In keratinocytes, TRIM21 is translocated from
the cytoplasm to the cell surface in response to UV light,
oxidative stress, nitric oxide (NO) or estradiol treatment
[57–62]. TRIM21 expression has also been reported to be
elevated in the brain microvasculature, which may be related
to brain vascular involvement in autoimmune diseases [63].
TRIM21 has an alternative splicing variant, named
Ro52β. The entire exon 4, comprising the C-terminal part of
the coiled-coil domain, is spliced oﬀ in Ro52β. So far Ro52β
has been detected only at the mRNA level and to date there
is no report showing the Ro52β protein, with the predicted
molecular weight of 45kDa [28, 64]. Ro52β transcript levels
are markedly increased in human fetal hearts between 14
weeksand16weeksofgestationanddiminishat22–25weeks
[64]. The expression levels of the two splicing variants have
been investigated also in salivary glands of patients with SS,
but no signiﬁcant diﬀerence in the levels of either variant
between patients and healthy controls has been detected in
this paper [65].
3. TRIM21 Functions
The RING domains of TRIM family members have been
shown to have E3 ubiquitin ligase activity, which mediates
ubiquitylationevents[33].Followingtheﬁrstdemonstration
of TRIM21 ubiquitin E3 ligase activity by Wada et al., several
reports supporting the conclusion have been published by
other groups [24, 38, 41, 66].
T h e r eh a v eb e e nm a n yp a p e r sr e p o r t i n gT R I M 2 1 -
interacting proteins (Table 2). IFN regulatory factors (IRFs),
a family of transcription factors that stimulates transcription
of type I IFN and other immune response genes after
activation, have been shown to be substrates of the TRIM21
ubiquitin ligase. TRIM21 interacts with IRF8, following
stimulation by IFN and TLR ligands, suggesting a role for4 International Journal of Rheumatology
Table 2: TRIM21-binding proteins.
Protein Molecular function of TRIM21 Functional output Reference
(1) Substrate of TRIM21 E3 ligase
IRF3 Proteasomal degradation Suppressing IFN-β production [68]
IRF7 Proteasomal degradation Suppressing IFN-α production [70]
IRF8 Transcriptional activation Promoting IL-12p40 production [41]
IgG Proteasomal degradation Neutralization of IgG-coated virion [82]
IKKβ Translocation to autophagosomes Suppressing NF-κB signaling [91]
UnpEL Unknown Unknown [39]
TRIM5α Translocation to cytoplasm Unknown [111]
(2) Proteins supporting TRIM21 E3 activity
Skp2 Facilitating p27 degradation Promoting S-phase progression [38]
Skp1 Facilitating p27 degradation Promoting S-phase progression [38]
Cul1 Facilitating p27 degradation Promoting S-phase progression [38]
βTrCP2 Unknown Unknown [38]
p62 Facilitating IRF8 degradation Suppressing IL-12p40 production [67]
TRIB2 Facilitating C/EBPα degradation Promoting lung tumorigenesis [85]
FADD Facilitating IRF7 degradation Suppressing IFN-α production [71]
(3) Proteins irrelevant to TRIM21 E3 activity
IRF3 Stabilization Promoting IFN-β production [69]
Daxx Unknown Unknown [84]
Flash Translocating Daxx to cytoplasm Unknown [84]
DCP2 Facilitating decapping activity Unknown [86]
this protein in innate immunity [41]. This interaction,
which occurs in the nucleus, mediates IRF8 ubiquitylation
and increases the ability of IRF8 to promote interleukin
(IL)-12p40 transcription in murine macrophage cell line.
Later, sequestosome 1 (also called p62), an adaptor protein
with multiple functions, was also shown to interact with
TRIM21 and IRF8, which leads to increased polyubiquityla-
tion and destabilization of IRF8 in stimulated macrophages,
resulting in attenuation of IL-12p40 expression [67]. There
are two contradictory reports as to the role of TRIM21
in IRF3 ubiquitylation. One group reported that TRIM21
ubiquitylates IRF3 following TLR3 or TLR4 stimulation,
which leads to its degradation at proteasome, resulting
in negative regulation of type I IFN [68]. Another group
showed that TRIM21 stabilizes IRF3 by interfering with
the interaction between peptidyl-prolyl cis/trans isomerase,
NIMA-interacting 1 (Pin1), and IRF3, thus enhancing
the strength and duration of primary antiviral response
[69]. TRIM21-mediated IRF7 ubiquitylation promotes the
degradation of IRF7 following TLR7 or TLR9 stimulation,
resulting in a decrease of IFN-α production [70]. It is also
reported that Fas-associated death domain (FADD) and
TRIM21 cooperatively ubiquitylate IRF7, interfere with the
ubiquitin ligase activity of TNF receptor-associated factor 6
(TRAF6) by aﬀecting phosphorylation status of IRF7, and
repress IFN-α activation in Sendai virus-infected cells [71].
Characterization of immune cells from TRIM21-deﬁcient
mice demonstrated that TRIM21 is required for polyubiqui-
tylation and degradation of IRF5 in addition to IRF3, IRF7,
and IRF8, although interaction between TRIM21 and IRF5
has not shown yet [42, 43, 70]. In sum, although the role of
TRIM21 in regulating the IFN pathway is still controversial,
multiple lines of evidence strongly suggest that TRIM21 is an
important regulator in innate immune responses.
TRIM21 may also have important roles in acquired
immunity. TRIM21 may regulate T-cell activation or prolif-
eration, since overexpression of TRIM21 has been shown to
increase IL-2 production in CD28-stimulated Jurkat T cells
[72]. Reduced IL-2 results in the suppression of activation-
induced cell death and increased longevity of autoreactive
T cells in patients with SLE [73]. In a murine B-cell line,
TRIM21 negatively regulates cell growth in steady state
and increases apoptotic cell death after activation via the
CD40 pathway [24]. Based on the antigen-driven immune
response hypothesis, the produced apoptotic cell debris,
which could be the source of TRIM21 autoantigen, may
induce the production of anti-TRIM21 antibodies [74].
These autoantibodies could cause the subsequent inﬂamma-
tory condition and create a positive feedback ampliﬁcation
loop of inﬂammation. Additionally, it also suggests that the
increased expression of the TRIM21 autoantigen in patients
may be directly involved in the reduced cellular proliferation
and increased apoptotic cell death observed in SLE and SS.
Another protein that has been well investigated as a
TRIM21-binding protein is IgG [75–80]. The interaction
was ﬁrst suspected from the unexpected observation that
normal human sera could precipitate TRIM21 [81]. Then
several groups reported that TRIM21 binds to the Fc region
of human IgG1,I g G 2,a n dI g G 4 via the PRYSPRY domain
with high aﬃnity (Kd = 37nM) [76, 78, 80]. The PRYSPRYInternational Journal of Rheumatology 5
domain binds to diﬀerent parts of the IgG Fc region from
where FcγR binds to. On the other hand, human TRIM21
doesnotseemtointeractwithmurineIgG[80].Althoughthe
physiological meaning of TRIM21-IgG interactions remains
unknown, it may play a role in the pathogenesis of SLE and
SS. Recently, Mallery et al. reported that TRIM21 rapidly
recruits incoming antibody-coated virus and targets it to
the proteasome via its E3 ubiquitin ligase activity, resulting
in degradation of virions in the cytosol [82]. Infection
experiments demonstrate that at physiological antibody
concentrations TRIM21 neutralizes viral infection. Based on
these data, the authors suggest a new interesting concept that
antibodies mediate an intracellular immune response and
protect cell interior and that TRIM21 acts as an intracellular
antibody receptor for the ubiquitin-proteasome system [83].
Nevertheless, it remains unclear how the proteasome deals
with such a large substrate as the viral capsid.
TRIM21 has been shown to interact with several addi-
tional proteins. The TRIM21-Skp2-SKp1-Cul1 complex
ubiquitylates and degrades the cyclin-dependent kinase in-
hibitor p27 and promotes S-phase progression in human
cell line [38]. TRIM21 associates with the apoptosis-related
proteins, Daxx and FLASH, and induces cytoplasmic local-
ization of Daxx in cooperation with FLASH [84]. TRIM21
interacts with tribbles homolog 2 (TRIB2) and leads to
degradation of a diﬀerentiation-inducing transcription fac-
tor CCAAT/enhancer-binding protein α (C/EBPα), causing
lung tumorigenesis [85]. TRIM21 binds to and activates
decapping enzyme 2 (DCP2), suggesting a role in mRNA
metabolism in response to cellular stimulation [86].
The rs660 polymorphism in TRIM21 correlates with
the age at which patients with sickle cell disease become
alloimmunized following red blood cell (RBC) transfusion
[87]. Because this polymorphism is found outside of the
TRIM21-coding regions, it has been proposed to play a role
in regulating levels of TRIM21 expression [20, 87]. Thus, it
has been hypothesized that rs660C/T leads to lower levels
of TRIM21 expression than rs660T/T, resulting in reduced
negative feedback responses and higher rates of alloimmu-
nization against transfused RBCs. However, depletion of
TRIM21 expression did not enhance transfusion-induced
humoral alloimmunization in murine model [88].
How do autoantibodies to TRIM21 in sera aﬀect the
function of TRIM21 inside cells? First, it should be clariﬁed
how autoantibodies meet intracellular TRIM21 molecules.
Recently, it has been reported that IgG can enter the
cytoplasm of nonimmune cells through the cell membrane
together with virus [82]. This suggests the possibility of
intracellular autoantigen-autoantibody interaction. Second,
we should know the eﬀect of autoantigen-autoantibody
interaction on the molecular function of TRIM21. A recent
reportshowsthatanti-TRIM21autoantibodiesinhibittheE3
ligase activity of TRIM21 by sterically blocking the E2/E3
interaction between TRIM21 and UBE2E1 [89]. Although
it still remains to be investigated whether enough anti-
TRIM21 autoantibodies can enter cells to inhibit TRIM21
function suﬃciently, this inhibition may contribute to the
pathogenesis of SLE and SS by inhibiting TRIM21-mediated
ubiquitylation.
4.Trim21-Knockout Mice
Two groups have recently disrupted the murine Trim21 gene
for analyses of TRIM21 function [42, 43]. They reported
markedly diﬀerent phenotypes for their mutant mice,
although there are some similarities. The Trim21
−/− mice
described by Yoshimi et al. live a normal life span with no
overt abnormal phenotypes [42]. Their immune cells show
normal composition and elicit comparable responses to
pathogen signals and antigen stimulation as cells of wild-
type mice. In addition, Yoshimi et al. noted about a twofold
increase in production of NF-κB-dependent cytokines, such
as IL-1β,T N F α, and IL-6, was observed in Trim21
−/−
ﬁbroblasts as compared to wild-type ﬁbroblasts. Data con-
sistent with this paper were published by another group
[90,91].Thatis,TRIM21downregulatesNF-κBsignallingby
monoubiquitylating IκB kinase β (IKKβ) and translocating
IKKβ to autophagosomes. Several Trim genes, Trim12,
Trim30,o rTrim34, encoded near Trim21 were found
upregulated in Trim21
−/− cells, suggesting that the absence
of TRIM21 protein in these mice was compensated by a
network of cross-talk among related TRIM members.
On the other hand, Espinosa et al. reported that
TRIM21-deﬁcient mice develop uncontrolled inﬂammation
andsystemicautoimmunityasaconsequenceofminortissue
injury caused by ear tagging [43]. However the mutant mice
still carried a C-terminally truncated Trim21 and expressed
the corresponding transcript [92, 93]. In these mice, the
general autoimmune pathology and neutrophil recruitment
to the site of injury were IL-23 dependent, as they were not
observed when the mice were crossed to IL-23p19-deﬁcient
mice. Bone-marrow-derived macrophages and spleno-
cytes from the mutant mice released more inﬂammatory
cytokines,IL-6,TNFα,typeIIFN,andIL-23,uponTLRacti-
vation as compared to wild type. Overall, these data demon-
strate that TRIM21 is induced by IFN activation of immune
cells, where it acts as a negative regulator of IFN signaling.
Although the possibility that diﬀerences in environmen-
tal factors between the colonies of the two laboratories could
account for the discrepancies cannot be ruled out, there are
marked diﬀerences in the gene disruption method used by
the two groups [92, 93]. First, in mice made by Espinosa
et al. the overexpressed truncated protein could act as a
dominant negative mutant, interfering with the function of
a number of TRIM family members, including the normal
TRIM21, and resulting in a stronger phenotype than the null
mutant reported by Yoshimi et al. Second, the mutant mice
reported by Espinosa et al. did not show a compensatory
increase in the expression of other Trim g e n e sa so b s e r v e d
in the null mutant, suggesting that the stronger phenotype is
due to a lack of the compensatory mechanisms. Anyway, the
results from these two mutant mice suggest that TRIM21 is a
negativeregulatorforproinﬂammatorycytokineproduction.
Further experiments using animal disease models are needed
for pursuing the proposed use of TRIM21 as a therapeutic
target in the future. For example, it will be interesting
to investigate whether disease severity of murine lupus
m o d e ls t r a i n s ,s u c ha sM R L / lpr, BWF1, and B6-Yaa,c a nb e
diminished by adenovirus-mediated Trim21 gene transfer.6 International Journal of Rheumatology
5. TRIM21 as a Possible Therapeutic
Target for SLE
Patients with SLE are usually treated with nonsteroidal anti-
inﬂammatory drugs (NSAIDs), glucocorticoids, antimalari-
als, and immunosuppressants, including cyclophosphamide,
azathioprine, mycophenolate mofetil, cyclosporine, tacroli-
mus, and methotrexate. Owing to the use of these drugs, the
prognosis of patients with SLE has dramatically improved in
the past. Nonetheless, rheumatologists sometimes encounter
cases in which it is diﬃcult to control the disease activity or
to continue the treatment due to serious side eﬀects.
In patients with SLE, increased expression of a subset
of IFN-inducible genes, collectively called “interferon signa-
ture,” is often observed [94]. Thus, the high level of type
I IFN and IFN-stimulated genes has been suspected to be
involved in the pathogenesis of SLE. pDCs produce a large
amount of type I IFN via the activation of TLR7 and TLR9
upon viral infection, and these cells are thought to be the
main source of IFN-α in patients with SLE [95, 96]. While
the number of pDC is reduced in the peripheral blood, many
pDCsinﬁltrateintotheskinandrenallesionsinpatientswith
SLE [97]. The serum levels of IFN are high in a subset of
SLE patients and correlate with the disease activity [98]. IFN
therapy of hepatitis C can lead to SLE as a side eﬀect [99].
Thus suppression of IFN signaling can be a hopeful strategy
for SLE treatment. TRIM21 negatively controls type I IFN
production via ubiquitylation of IRFs as discussed above.
Because TRIM21 expression is increased by type I IFN, the
role of TRIM21 as a negative regulator increases late after
inﬂammation.Thus,TRIM21couldrepressandturnoﬀtype
IIFNproduction,contributingtoprotectionfromprolonged
overproduction of type I IFN and the pathogenesis of SLE.
Therefore, increasing E3 activity of TRIM21 in type IFN-
producing cells, such as pDCs and ﬁbroblasts, may also be
a useful strategy for the treatment of SLE.
NF-κB plays a pivotal role in inﬂammation through its
abilitytoinducetranscriptionofproinﬂammatorycytokines,
chemokines, and adhesion molecules [100]. In SLE, for
example, in situ expression of activated NF-κB is increased in
glomerular endothelial cells, mesangial cells, and inﬁltrating
cells in class IV lupus nephritis, along with upregulation
of TNFα,I L - 1 β, IL-6, and ICAM-1 expression [101]. Some
of the eﬀects of glucocorticoids used in SLE treatment
are mediated through the inhibition of NF-κB activation.
The NF-κB activation is mediated by IKK via phosphory-
lation of IκB. TRIM21 downregulates NF-κB signalling by
monoubiquitylating IKKβ, a subunit of IKK complex, and
translocating IKKβ to autophagosomes [42, 90, 91]. Because
TRIM21expressionisincreasedbytypeIIFNasnotedabove,
the activity of TRIM21 in inhibiting NF-κB signalling can
augment at a late phase in inﬂammation. Thus, TRIM21
could have an essential physiological role in turning oﬀ
the NF-κB signalling, avoiding prolonged overproduction
of proinﬂammatory cytokines, chemokines, and adhesion
molecules. Therefore, a strategy for increasing E3 activity of
TRIM21 in macrophages and in many cell types may also be
useful for the treatment of SLE.
TRIM21 is substantially induced by type I IFN, type II
IFN, and TLR ligands in DCs, macrophages, and ﬁbroblasts.
This implies the physiological signiﬁcance of TRIM21 in
an inﬂammatory state in these cells. Thus, increasing the
expression of TRIM21 in these cells can be of advantage to
thepatients.Additionally,Tcellsmaybeanimportantsubset
for the therapy targeting TRIM21, because TRIM21 is highly
expressed in T cells among leukocyte subsets, suggesting the
signiﬁcance of TRIM21 in T cells. Serum IL-2 levels are
reduced in patients with SLE, resulting in the suppression
of activation-induced cell death and increased life-span of
autoreactive T cells [73]. This also likely causes an increased
risk of infection, one of the major prognosis factors for
SLE [73]. Because TRIM21 seems to positively regulate IL-
2p r o d u c t i o nb yTc e l l s[ 72], increasing TRIM21 activity in T
cells may be a strategy worthy of consideration.
Diﬀerentiation of T-cell subsets is biased in patients with
SLE. Increased IL-6 production by antigen presenting cells
and decreased IL-2 secretion by T cells inhibit the develop-
ment of regulatory T cells and promote the diﬀerentiation
of IL-17-producing T (Th17) cells. Given that Th17 cells
are found not only in the peripheral blood but also in the
inﬂamed kidney in patients with SLE [102, 103], blockade of
IL-17 or IL-23, which is important for IL-17 production by
Th17cells,mayhelptocontrolSLEpathogenesis.AsTRIM21
can negatively regulate IL-23-Th17 pathway [43], increased
E3 activity by TRIM21 may contribute to the regulation of
these cytokines.
Inordertosuppressaberrantantibodyproduction,mod-
ulating the number and the function of B cells has been
regardedasapromisingmeansforcontrollingSLE.Although
smallstudiesandcaseseriesusingachimericanti-CD20anti-
body, rituximab, in patients with SLE have initially shown
promising data [104–106], a placebo-controlled randomized
trial of rituximab in patients with moderate-to-severe SLE
failed to observe eﬃcacy of rituximab [107]. Belimumab,
a human monoclonal antibody that neutralizes a B-cell
survivalfactor,B-lymphocytestimulator(BLyS),hasreceived
an FDA approval for the treatment of patients with active,
autoantibody-positive SLE receiving standard therapy [108].
Because TRIM21 is suggested to negatively regulate B-cell
growth and increase apoptotic cell death [24], it may be
eﬀective as a B-cell-based treatment of SLE. However, there
is also a possibility that increased apoptotic death in B cells
may exacerbate the pathogenesis of SLE. On the other hand,
increased IL-6 promotes antibody production in humans
and mice with lupus [109]. A monoclonal antibody against
the IL-6 receptor, tocilizumab, has been reported to be
promising in a phase I clinical trial [110]. TRIM21 may sup-
press antibody production by suppressing IL-6 production.
In sum, increasing the activity of TRIM21 could be
beneﬁcial in controlling many aspects of SLE disease activity.
Although altering the broad range of activity by TRIM21
could suggest potential risk of a variety of side eﬀects,
TRIM21-targeting therapy may provide a new avenue of SLE
treatment, which may oﬀer multiple beneﬁts unattainable by
existing therapies.International Journal of Rheumatology 7
6. Conclusions
SLE is an autoimmune disease, in which immune system ab-
errations as well as heritable, hormonal, and environmental
factors contribute to the manifestation of organ damage.
Recent data suggest that the autoantigen TRIM21 negatively
regulates the development of autoimmune diseases and in-
ﬂammation in autoimmune pathogenesis. Thus, TRIM21-
targeted therapy may oﬀer a useful new strategy for treating
autoimmune diseases.
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